ArticleScience advances2025
Ultrabright difuranfluoreno-dithiophen polymers for enhanced afterglow imaging of atherosclerotic plaques.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rational Design and Development of Organic Afterglow Nanoparticles for Image-Guided Interventions.Small methods · 2026Review
- Silent Myocardial Infarction Revisited: Immuno-metabolic Mechanisms, Multimodal Biomarkers, and Translational Diagnostics.Journal of cardiovascular translational research · 2026Review
- Thiol-polarity dual cascade-triggered two-photon imaging of protein unfolding for early atherosclerosis diagnosis.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases, including stroke driven by atherosclerosis, remain a leading global health concern. Current diagnostic imaging modalities such as magnetic resonance imaging fail to characterize oxidative stress within atherosclerotic plaques. Here, we introduce difuranfluoreno-dithiophen-based polymers designed for afterglow imaging, offering ultrabright luminescence, ultralow-power excitation (0.087 milliwatts per square centimeter), and ultrashort acquisition times (0.01 seconds). Through a molecular engineering strategy, we have optimized polymers for enhanced reactive oxygen species (ROS) generation capability, ROS capturing capability, and fluorescence quantum yield, resulting in an increase in afterglow intensity (~130-fold) compared to commonly used 2-methoxy-5-(2'-ethylhexyloxy)-1,4-phenylenevinylene polymer (MEHPPV). Additionally, we have developed ratiometric afterglow nanoparticles doped with oxidative stress-responsive molecules, enabling imaging of oxidative stress markers in atherosclerotic plaque. This approach provides a tool for cardiovascular imaging and diagnostics, which is conducive to the auxiliary diagnosis and risk stratification of atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.